Five years of exemestane as initial therapy compared to tamoxifen followed by exemestane for a total of 5 years: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone receptor-positive early breast cancer

被引：1
|
作者：
Hasenburg, A. [1 ]
van de Velde, C. J. H. [2 ]
Seynaeve, C. [3 ]
Rea, D. W. [4 ]
Vannetzel, J. [5 ]
Paridaens, R. [6 ]
Markopoulos, C. [7 ]
Hozumi, Y. [8 ]
Putter, H. [2 ]
Jones, S. E. [9 ]
机构：
[1] Univ Med Ctr, Freiburg, Germany
[2] Univ Med Ctr, Leiden, Netherlands
[3] Erasmus MC, Rotterdam, Netherlands
[4] Univ Birmingham, Birmingham, W Midlands, England
[5] Inst Sein Henri Hartmann, Neuilly Sur Seine, France
[6] Univ Hosp Gasthuisberg, Louvain, Belgium
[7] Univ Med Sch, Athens, Greece
[8] Jichi Med Univ, Shimotsuke, Japan
[9] US Oncol Res, Med Oncol, Houston, TX USA
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 03期
关键词：
D O I：
10.1016/S1359-6349(10)70047-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：62 / 62
页数：1
相关论文
共 50 条
  • [41] Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27-A Randomized Controlled Phase III Trial
    Goss, Paul E.
    Ingle, James N.
    Pritchard, Kathleen I.
    Ellis, Matthew J.
    Sledge, George W.
    Budd, G. Thomas
    Rabaglio, Manuela
    Ansari, Rafat H.
    Johnson, David B.
    Tozer, Richard
    D'Souza, David P.
    Chalchal, Haji
    Spadafora, Silvana
    Stearns, Vered
    Perez, Edith A.
    Liedke, Pedro E. R.
    Lang, Istvan
    Elliott, Catherine
    Gelmon, Karen A.
    Chapman, Judy-Anne W.
    Shepherd, Lois E.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (11) : 1398 - 1404
  • [42] Comparison of cost-effectiveness of aromatase inhibitors letrozole, anastrozole or exemestane versus tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Canadian perspective
    El Ouagari, K.
    Kamon, J.
    Kaura, S.
    EJC SUPPLEMENTS, 2007, 5 (04): : 210 - 211
  • [43] Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
    Kaufmann, M
    Bajetta, E
    Dirix, LY
    Fein, LE
    Jones, SE
    Zilembo, N
    Dugardyn, JC
    Nasurdi, C
    Mennel, RG
    Cervek, J
    Fowst, C
    Polli, A
    di Salle, E
    Arkhipov, A
    Piscitelli, G
    Miller, LL
    Massimini, G
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (07) : 1399 - 1411
  • [44] First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen.
    Coombes, R. C.
    Paridaens, R.
    Jassem, J.
    Van de Velde, C. J.
    Delozier, T.
    Jones, S. E.
    Hall, E.
    Kilburn, L. S.
    Snowdon, C. F.
    Bliss, J. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 9S - 9S
  • [45] A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer
    Freedman, O. C.
    Amir, E.
    Hanna, W.
    Kahn, H.
    O'Malley, F.
    Dranitsaris, G.
    Cole, D. E. C.
    Verma, S.
    Folkerd, E.
    Dowsett, M.
    Clemons, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2010, 119 (01) : 155 - 161
  • [46] A randomized trial exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer
    O. C. Freedman
    E. Amir
    W. Hanna
    H. Kahn
    F. O’Malley
    G. Dranitsaris
    D. E. C. Cole
    S. Verma
    E. Folkerd
    M. Dowsett
    M. Clemons
    Breast Cancer Research and Treatment, 2010, 119 : 155 - 161
  • [47] Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)-a randomised controlled trial of exemestane versus continued tamoxifen after 2-3 years tamoxifen
    Bertelli, G.
    Hall, E.
    Ireland, E.
    Snowdon, C. F.
    Jassem, J.
    Drosik, K.
    Karnicka-Mlodkowska, H.
    Coombes, R. C.
    Bliss, J. M.
    ANNALS OF ONCOLOGY, 2010, 21 (03) : 498 - 505
  • [48] Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Yamamoto, Yutaka
    Ishikawa, Takashi
    Hozumi, Yasuo
    Ikeda, Masahiko
    Iwata, Hiroji
    Yamashita, Hiroko
    Toyama, Tatsuya
    Chishima, Takashi
    Saji, Shigehira
    Yamamoto-Ibusuki, Mutsuko
    Iwase, Hirotaka
    BMC CANCER, 2013, 13
  • [49] International comparison of the cost-effectiveness of 5 years letrozole or anastrozole compared to 5 years tamoxifen for early breast cancer in hormone receptor-positive postmenopausal women: Belgium, Canada, UK, and US analyses
    Kaura, S.
    Karnon, J.
    di Trapani, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [50] Randomized controlled trial of toremifene 120 mg compared with exemestane 25 mg after prior treatment with a non-steroidal aromatase inhibitor in postmenopausal women with hormone receptor-positive metastatic breast cancer
    Yutaka Yamamoto
    Takashi Ishikawa
    Yasuo Hozumi
    Masahiko Ikeda
    Hiroji Iwata
    Hiroko Yamashita
    Tatsuya Toyama
    Takashi Chishima
    Shigehira Saji
    Mutsuko Yamamoto-Ibusuki
    Hirotaka Iwase
    BMC Cancer, 13
12345